CG Oncology (CGON) Retained Earnings (2023 - 2026)
CG Oncology's (CGON) quarterly Retained Earnings came in at $1.5 billion in Q1 2026, up 706.56% YoY from $189.8 million in Q1 2025, and up 503.97% on a QoQ basis from -$379.0 million in Q4 2025.
CG Oncology (CGON) Retained Earnings (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Retained Earnings data on file, last reported at $1.5 billion in Q1 2026.
- Quarterly Retained Earnings rose 706.56% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 706.56% YoY) and the FY2025 annual result came in at -$379.0 million, down 139.84% from the prior year.
- Retained Earnings climbed to $1.5 billion in Q1 2026, from -$379.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.5 billion in Q1 2026 to a low of -$379.0 million in Q4 2025.
- A 4-year average of $512.0 million and a median of $719.4 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 13804.56% — and 2025, when it sank 139.84%.
- Tracing CGON's Retained Earnings over 4 years: stood at $6.8 million in 2023, then surged by 13804.56% to $951.4 million in 2024, then slumped by 139.84% to -$379.0 million in 2025, then surged by 503.97% to $1.5 billion in 2026.
- The last three Retained Earnings figures came in at $1.5 billion (Q1 2026), -$379.0 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 1.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.55 Bn |
| Mar 31, 2026 | 1.53 Bn |
| Dec 31, 2025 | -378.98 Mn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 964.21 Mn |
| Mar 31, 2025 | -252.40 Mn |
| Dec 31, 2024 | 951.35 Mn |
| Sep 30, 2024 | 722.95 Mn |
| Jun 30, 2024 | -165.78 Mn |
| Mar 31, 2024 | 715.81 Mn |
| Dec 31, 2023 | 6.84 Mn |